Tiburio is advancing a pipeline of Phase 2 ready assets
Tiburio’s clinical stage pipeline is based on novel dopamine-somatostatin chimeric molecules for the treatment of severe neuroendocrine disorders. This unique class of chimeric compounds combines structural elements of both dopamine and somatostatin giving them the ability to bind and activate both receptors. Studies suggest that these chimeric compounds may facilitate physical interactions between dopamine and somatostatin receptors that results in enhanced activity, offering new potential for a variety of diseases with unmet need.
| Compound | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| TBR-760 For treatment of NFPA. |
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
| TBR-065 For treatment of rare endocrine disorders. |
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|